Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Sustained Clinical and Quality-of-Life Benefits After Long-Term Intermittent Levosimendan Therapy in Advanced Heart Failure: Experience from Over 550 Infusions
Session:
Sessão de Posters 50 - Terapêuticas avançadas na insuficiência cardíaca e em populações especiais
Speaker:
Rodrigo Neves Brandão
Congress:
CPC 2026
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.2 Chronic Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Rodrigo Neves Brandão; Luís Cotrim; Inês Madeira Santos; Inês Pereira Miranda; Filipa Gerardo; Manuel Ribeiro; Célia Henriques; Mariana Passos; Ana Oliveira Soares; Inês Fialho; David Roque
Abstract
<p><strong>Background:</strong> Levosimendan, a calcium-sensitizing inotrope, has demonstrated hemodynamic and symptomatic benefits in patients with advanced heart failure (AHF), potentially improving clinical stability and quality of life. </p> <p><strong>Objectives: </strong>Evaluate the impact of intermittent levosimendan infusions (ILI) on functional class, biomarkers, and six-month clinical outcomes.</p> <p><strong>Methods:</strong> This retrospective, single-center study included 59 patients with AHF receiving ILI. Clinical and laboratory parameters were assessed at baseline and after six months of therapy. Variables compared included the number of heart failure (HF) hospitalizations, NYHA functional class, Seattle Heart Failure Model (SHFM) scores (1- and 5-year survival estimates), and NT-proBNP levels.</p> <p><strong>Results:</strong> The cohort included 59 patients, 77% men (n=46), with a mean age of 67 ± 12.9 years and a median BMI of 25 (IQR 21–27) kg/m². All patients had HFrEF, most commonly ischemic etiology (n=33, 55%), followed by idiopathic dilated cardiomyopathy (n=16, 27%). Baseline left ventricular ejection fraction was 24.6% (IQR 19.5–29.5), and NT-proBNP was 9,805 pg/mL (IQR 3,292–12,310). Before treatment, 97% of patients were in NYHA class III. By October 2025, 31.7% of patients (n=19) had died, 15% (n=9) due to heart failure. Among 17 patients initially considered for advanced therapies, 3 underwent cardiac transplant and 1 received a left ventricular assistance device (LVAD), while 72% of patients (n=43) were treated with palliative intent for symptomatic improvement. Following initiation of levosimendan cycles, a significant reduction was observed in HF hospitalizations (p < 0.001) and an improvement in NYHA class (p < 0.001). Quality of life significantly improved, reflected by higher SHFM scores both at 1 year (81.7 ± 12.4 vs. 88.2 ± 9.2; p = 0.040) and 5 years (42.8 ± 24.9 vs. 57.5 ± 22.6; p = 0.018). NT-proBNP levels decreased markedly after six months (9,805 ± 10,709 pg/mL vs. 4,698 ± 5,789 pg/mL; p < 0.001), indicating improved decongestion and hemodynamic balance.</p> <p><strong>Conclusions:</strong> ILI were associated with a significant reduction in HF hospitalizations, improvement in functional class, and enhancement of quality-of-life scores, accompanied by a substantial decrease in NT-proBNP levels. These findings support the role of levosimendan as an effective therapeutic strategy for optimizing clinical status and prognosis in patients with advanced heart failure- either as palliative therapy for symptom control and quality-of-life improvement, or as a bridge to heart transplantation or LVAD implantation</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site